

5-Minute Journal Club: Defining the Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer — Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The ongoing TROPION-Breast03 trial is evaluating datopotamab deruxtecan (Dato-DXd) in which of the following settings?
 - a. As neoadjuvant therapy for patients with HR-positive, HER2-negative or HER2-low localized breast cancer
 - b. In combination with durvalumab for patients with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy
 - c. As single-agent adjuvant therapy for HR-positive, HER2-negative breast cancer
 - d. As first-line monotherapy for metastatic HR-positive, HER2-positive metastatic breast cancer
2. What was the approximate incidence of oral mucositis/stomatitis in patients with previously treated advanced HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
 - a. 12%
 - b. 30%
 - c. 57%
 - d. 90%
3. Dato-DXd is currently ...
 - a. Not approved by the FDA
 - b. Approved for HR-positive breast cancer
 - c. Approved for EGFR-mutant lung cancer
 - d. Both b and c
4. What was the approximate objective response rate (ORR) observed with sacituzumab tirumotecan as first-line therapy for patients with advanced TNBC in the Phase II OptiTROP-Breast05 trial?
 - a. 25%
 - b. 40%
 - c. 55%
 - d. 70%
5. Phase III data suggest that sacituzumab govitecan improves outcomes for patients with metastatic TNBC in which of the following settings?
 - a. As monotherapy for PD-L1-negative disease
 - b. In combination with pembrolizumab for PD-L1-positive disease
 - c. Both a and b
 - d. None of the above